FI20116138L - Matriisi bioaktiivisten aineiden hallittuun vapauttamiseen - Google Patents

Matriisi bioaktiivisten aineiden hallittuun vapauttamiseen Download PDF

Info

Publication number
FI20116138L
FI20116138L FI20116138A FI20116138A FI20116138L FI 20116138 L FI20116138 L FI 20116138L FI 20116138 A FI20116138 A FI 20116138A FI 20116138 A FI20116138 A FI 20116138A FI 20116138 L FI20116138 L FI 20116138L
Authority
FI
Finland
Prior art keywords
matrix
controlled release
bioactive substances
bioactive
substances
Prior art date
Application number
FI20116138A
Other languages
English (en)
Swedish (sv)
Other versions
FI130619B (fi
Inventor
Antti Laukkanen
Ruzica Kolakovic
Leena Peltonen
Timo Laaksonen
Jouni Hirvonen
Heikki Lyytikaeinen
Harri Jukarainen
Pirjo Kortesuo
Original Assignee
Upm Kymmene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upm Kymmene Corp filed Critical Upm Kymmene Corp
Priority to FI20116138A priority Critical patent/FI130619B/fi
Priority to PCT/FI2012/051121 priority patent/WO2013072563A1/en
Priority to EP12799232.9A priority patent/EP2779996B1/en
Priority to US14/358,141 priority patent/US11389537B2/en
Priority to JP2014541721A priority patent/JP6178329B2/ja
Publication of FI20116138L publication Critical patent/FI20116138L/fi
Priority to HK15102889.3A priority patent/HK1202418A1/xx
Application granted granted Critical
Publication of FI130619B publication Critical patent/FI130619B/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI20116138A 2011-11-15 2011-11-15 Matriisi bioaktiivisten aineiden hallittuun vapauttamiseen FI130619B (fi)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FI20116138A FI130619B (fi) 2011-11-15 2011-11-15 Matriisi bioaktiivisten aineiden hallittuun vapauttamiseen
PCT/FI2012/051121 WO2013072563A1 (en) 2011-11-15 2012-11-15 Drug delivery system for sustained delivery of bioactive agents
EP12799232.9A EP2779996B1 (en) 2011-11-15 2012-11-15 Drug delivery system for sustained delivery of bioactive agents
US14/358,141 US11389537B2 (en) 2011-11-15 2012-11-15 Drug delivery system for sustained delivery of bioactive agents
JP2014541721A JP6178329B2 (ja) 2011-11-15 2012-11-15 生物活性剤の持続性送達のためのドラッグデリバリーシステム
HK15102889.3A HK1202418A1 (en) 2011-11-15 2015-03-23 Drug delivery system for sustained delivery of bioactive agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20116138A FI130619B (fi) 2011-11-15 2011-11-15 Matriisi bioaktiivisten aineiden hallittuun vapauttamiseen

Publications (2)

Publication Number Publication Date
FI20116138L true FI20116138L (fi) 2013-05-16
FI130619B FI130619B (fi) 2023-12-15

Family

ID=47351708

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20116138A FI130619B (fi) 2011-11-15 2011-11-15 Matriisi bioaktiivisten aineiden hallittuun vapauttamiseen

Country Status (6)

Country Link
US (1) US11389537B2 (fi)
EP (1) EP2779996B1 (fi)
JP (1) JP6178329B2 (fi)
FI (1) FI130619B (fi)
HK (1) HK1202418A1 (fi)
WO (1) WO2013072563A1 (fi)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI125942B (fi) 2013-07-26 2016-04-15 Upm Kymmene Corp Nanofibrilliselluloosakoostumuksen modifiointimenetelmä
FI126120B (fi) 2014-12-22 2016-06-30 Upm Kymmene Corp Prosessi hapetetun nanofibrilliselluloosan hydrogeelin tuottamiseksi
FI125882B (fi) 2014-12-22 2016-03-31 Upm Kymmene Corp Nanofibrilliselluloosan hydrogeelin lämpökäsittely
FI125883B (fi) 2014-12-22 2016-03-31 Upm Kymmene Corp Katalyyttisesti hapetetun nanofibrilliselluloosan hydrogeelin käsittely
FI127834B (fi) * 2015-06-04 2019-03-29 Upm Kymmene Corp Prosessi nanofibrilliselluloosan hydrogeelin tuottamiseksi
US11173130B2 (en) * 2015-09-24 2021-11-16 Massachusetts Eye And Ear Infirmary Drug delivery system and methods of use
WO2017123577A1 (en) * 2016-01-12 2017-07-20 Repros Therapeutics Inc. Trans-clomiphene and progesterone receptor antagonist combination therapy for treating hormone-dependent conditions
EP3481427A4 (en) * 2016-07-08 2020-01-22 Cellutech AB MEDICINAL CARRIER WITH SOLID CELLULAR MATERIAL COMPRISING CELLULOSE NANOFIBERS (CNF), SOLID CELLULAR MATERIAL WITH CLOSED ALVEOLS
JP7150603B2 (ja) * 2016-08-08 2022-10-11 日本製紙株式会社 セルロースナノファイバー分散液の評価方法
DK3335695T3 (da) * 2016-12-15 2020-04-20 Upm Kymmene Corp Fremgangsmåde til frysetørring af hydrogel omfattende nanofibrillær cellulose, frysetørret medicinsk hydrogel omfattende nanofibrillær cellulose og hydrogel omfattende nanofibrillær cellulose
EP3335696B1 (en) * 2016-12-15 2019-12-18 UPM-Kymmene Corporation A method for drying cell-free tissue extract in a hydrogel comprising nanofibrillar cellulose and a dried hydrogel comprising nanofibrillar cellulose and cell-free tissue extract
WO2019108887A1 (en) * 2017-11-30 2019-06-06 Warner Babcok Institute For Green Chemistry, Llc Products comprising plant-based micro fibers
KR102200787B1 (ko) * 2017-12-29 2021-01-12 한경대학교 산학협력단 나노셀룰로오스를 이용한 습윤성 탄력붕대
EP3616730A1 (en) 2018-08-28 2020-03-04 UPM-Kymmene Corporation Composition or matrix for storage of bacteriophages comprising nanofibrillar cellulose
JP7147490B2 (ja) * 2018-11-07 2022-10-05 凸版印刷株式会社 徐放性複合粒子、徐放性複合粒子の製造方法及び乾燥粉体
HUP1900226A1 (hu) * 2019-06-21 2020-12-28 Hummel Zoltan Dr Hidrofil mikrobiális cellulóz nanorostokat tartalmazó hordozóanyag (gél) a bélnyálkahártya állapotának javítására
EP3791864A1 (en) * 2019-09-13 2021-03-17 UPM-Kymmene Corporation Method for preparing pharmaceutical composition and pharmaceutical composition
EP3791858A1 (en) * 2019-09-13 2021-03-17 UPM-Kymmene Corporation Injectable pharmaceutical formulation
BR102020007749A2 (pt) * 2020-04-17 2021-11-03 Edson Luiz Peracchi Implante subcutâneo reabsorvível de longa duração com liberação controlada de substância farmacologicamente ativa pré-concentrada em polímero para tratamento da endometriose
WO2022118104A1 (en) 2020-12-01 2022-06-09 3M Innovative Properties Company Article for storage of bacteriophages and method thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04243819A (ja) * 1991-01-25 1992-08-31 Grelan Pharmaceut Co Ltd 徐放性製剤
US5405953A (en) * 1993-08-03 1995-04-11 Biocontrol Incorporated Microfibrillated oxycellulose
JP4308336B2 (ja) * 1997-03-14 2009-08-05 株式会社日本吸収体技術研究所 ミクロフィブリル状微細繊維構造体およびその製造方法
WO2002022172A2 (en) * 2000-09-14 2002-03-21 University Of Iowa Research Foundation Powdered/microfibrillated cellulose
JP2006160626A (ja) * 2004-12-03 2006-06-22 Kyowa Hakko Kogyo Co Ltd 徐放化方法
JP2006160627A (ja) * 2004-12-03 2006-06-22 Kyowa Hakko Kogyo Co Ltd 時限放出化方法
US8951551B2 (en) 2005-08-31 2015-02-10 Board Of Regents, The University Of Texas System Multiribbon nanocellulose as a matrix for wound healing
CN101437594B (zh) * 2006-02-13 2012-07-04 唐纳森公司 包括细纤维和反应、吸附或吸收颗粒的过滤网
CN101172164A (zh) * 2006-11-03 2008-05-07 中国科学院化学研究所 可生物降解及吸收的生物高分子纳米纤维膜材料及其制法和用途
AU2008344471B2 (en) 2007-12-28 2012-12-20 Nippon Paper Industries Co., Ltd. Processes for producing cellulose nanofibers, cellulose oxidation catalysts and methods for oxidizing cellulose
US20100159046A1 (en) * 2008-12-19 2010-06-24 Xylos Corporation Minimal tissue attachment implantable materials
FI20095638A0 (fi) 2009-06-09 2009-06-09 Valtion Teknillinen Hydrofobiineja aktiivisten aineiden dispergointiin
FI123988B (fi) 2010-10-27 2014-01-31 Upm Kymmene Corp Soluviljelymateriaali
US8758826B2 (en) * 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods

Also Published As

Publication number Publication date
HK1202418A1 (en) 2015-10-02
JP6178329B2 (ja) 2017-08-09
EP2779996B1 (en) 2024-04-10
JP2014533296A (ja) 2014-12-11
EP2779996A1 (en) 2014-09-24
US20140322327A1 (en) 2014-10-30
WO2013072563A1 (en) 2013-05-23
FI130619B (fi) 2023-12-15
US11389537B2 (en) 2022-07-19

Similar Documents

Publication Publication Date Title
FI20116138L (fi) Matriisi bioaktiivisten aineiden hallittuun vapauttamiseen
SMT201600271B (it) BENZOSSAZEPINONI FUSI COME MODULATORI DI CANALl IONICI
DK2694038T3 (da) Farmaceutisk sammensætning
CO6791604A2 (es) Compuesto para liberación controlada de agentes de tratamiento de pozos
DK2787975T3 (da) Robuste formuleringer med kontrolleret frigivelse
EP2714015A4 (en) SOLID DOSAGE FORMS WITH CONTROLLED RELEASE
CO6801733A2 (es) Silicato de zirconio microporoso para el tratamiento de la hipercalemia
BR112013022112A2 (pt) composição
ZA201307862B (en) Controlled release pharmaceutical dosage forms
BR112013022102A2 (pt) composição
DK2686017T3 (da) Oftalmisk sammensætning
BR112013029316A2 (pt) micro-partícula injetável de liberação controlada
BR112014004395A2 (pt) composição
DK3395357T3 (da) Sammensætning til kontrolleret ovariestimulering
CO6900117A2 (es) Formulaciones peptídicas de liberación controlada
DK2783152T3 (da) Trykafgivelsessystem
BR112013033808A2 (pt) composição
DE112012003251A5 (de) Ausrücksystem
DE112012003262A5 (de) Ausrücksystem
BR112015008572A2 (pt) formulações de liberação modificada para oprozomib
ES2721400T8 (es) Composición de Diclofenaco
BR112014009319A2 (pt) compostos farmacêuticos
IL236465A0 (en) Pharmaceutical composition for delayed release of active substances
BR112013031686A2 (pt) fusão de moléculas bioativas
BR112014007030A2 (pt) composição